Testing a three-drug combination for elderly patients with an aggressive blood cancer

Plain-English translation of NCT06530511 on ClinicalTrials.gov ↗ · Source last updated February 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a three-drug combination called PRO — which includes polatuzumab, , and — to treat an aggressive type of blood cancer in older adults who may be frail or not strong enough for standard treatments. The research team wants to see how well this medication works and whether it is safe in this particular group of patients. The trial will enroll about 30 people over multiple medical centers.

Many older adults with this blood cancer are too frail or have too many other health problems to receive the standard, more intense treatments. Doctors need to find gentler but still effective treatment options for these patients, and this trial is testing whether this medication combination might be a better choice.

Do you qualify?

You likely qualify if…

you have been diagnosed with diffuse large B-cell lymphoma (a type of aggressive blood cancer) that has not been treated before
you are 60 years old or older and considered frail or medically unfit by your doctor
you have a specific subtype of this cancer called non-GCB type
you have at least one measurable tumor on imaging (a lymph node larger than 1.5 cm or another tumor larger than 1.0 cm)
you have adequate organ function (healthy kidneys, liver, and blood counts) based on blood tests
you have a life expectancy of at least 12 weeks

You likely don't qualify if…

you have uncontrolled heart disease, stroke risk, severe blood clotting problems, or severe immune system disorders
you have very low blood cell counts or abnormal liver or kidney function tests
you have HIV infection or untreated hepatitis B
you are currently taking certain medications that interact with the study drugs (your doctor can tell you if yours are affected)
you have difficulty swallowing pills or serious digestive problems like inflammatory bowel disease or bowel obstruction

What participation looks like

You will receive the treatment in 21-day cycles. Two of the medications are given by IV infusion on the first day of each cycle, and the third medication is a capsule you take by mouth once daily for all 21 days. You will need to visit the clinic regularly for blood tests, imaging scans, and check-ups to monitor how you are responding to the treatment and to watch for any side effects. The study will track how well the treatment works at controlling your cancer.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(2 sites)

China

Affiliated hospital of Nantong University, Nantong, Jiangsu

Jiangsu Province Hospital, Nanjing